As filed with the U.S. Securities and Exchange Commission on December 22, 2025 Registration No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ____________________________ ESTRELLA IMMUNOPHARMA, INC. (Exact Name of Registrant as Specified in its Charter) ____________________________ (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 6770 86-1 ...

Core Insights - HCW Biologics Inc. has presented studies indicating that its proprietary fusion protein HCW9206 offers a new pathway for generating CAR-T cells with enhanced function and reduced manufacturing costs [2][3] - The research shows that HCW9206 outperforms standard CAR-T production methods, leading to improved persistence and efficacy of CAR-T cells in treating various diseases [2][3] Company Overview - HCW Biologics is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies targeting chronic inflammation and related diseases [4][5] - The company has established a GMP master cell bank for HCW9206 and filed a drug master file with the FDA, indicating readiness for commercial partnerships [3][4] Product Development - HCW9206 is designed to deliver synergistic signals from three immune-stimulatory cytokines, enhancing the production of stem cell-like memory T cells (Tscm) which are crucial for effective CAR-T therapies [2][3] - The company has developed additional drug discovery technologies, including the TRBC platform, which allows for the creation of various immunotherapeutic compounds targeting cancer and autoimmune diseases [5]